Francesca Sampogna

Dr. Francesca Sampogna

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2005 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
CFCristina Fortes
Cristina Fortes
SMSimona Mastroeni
Simona Mastroeni
KLKaren Leffondré
Karen Leffondré
FSFrancesca Sampogna
Francesca Sampogna
FMFranco Melchi
Franco Melchi
DADamiano Abeni
Damiano Abeni
Psoriasis is a chronic, persistent, lifelong disease with a reported point prevalence of 0.8 to 2.8 in the general population.1 Psoriasis is characterized by scaly, red cutaneous plaques that contain inflammatory infiltrates and epidermal hyperproliferation.2 Although psoriasis is not a life-threatening disease, cure is seldom achieved, and its impact on patient health-related quality of life is dramatic.3-6 The disability experienced by patients with psoriasis is comparable with that of patients with other chronic illnesses, such as heart disease, diabetes mellitus, cancer, and depression.7

1 April 2017 in Acta Dermato-Venereologica
Verified
Journal Article
Open access
FSFrancesca Sampogna
Francesca Sampogna
DAD Abeni
D Abeni
UGU Gieler
U Gieler
Lucia Tomas-AragonesLucia Tomas-Aragones
Lucia Tomas-Aragones
LLL Lien
L Lien
FDF Dalgard
F Dalgard
Skin conditions may have a strong impact on patients’ sexual life, and thus influence personal rel...

1 March 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
FDFlorence J. Dalgard
Florence J. Dalgard
ÅSÅke Svensson
Åke Svensson
JHJon Anders Halvorsen
Jon Anders Halvorsen
UGUwe Gieler
Uwe Gieler
CSChristina Schut
Christina Schut
JKJörg Kupfer
Jörg Kupfer
Itch is a highly prevalent and multidimensional symptom. We aimed to analyze the association between itch and mental health in dermatological patients. This multicenter study is observational and cross-sectional and was conducted in dermatological clinics across 13 European countries. A total of 3,530 patients and 1,094 healthy controls were included. Patients were examined clinically. Outcome measures were itch (presence, chronicity, and intensity), the Hospital Anxiety and Depression Scale, EQ-5D visual analogue scale, sociodemographics, suicidal ideation, and stress (negative life events and economic difficulties). Ethical approval was obtained. Results showed significant association between the presence of itch in patients and clinical depression (odds ratio, 1.53; 95% confidence interval, 1.15-2.02), suicidal ideation (odds ratio, 1.27; 95% confidence interval, 1.01-1.60), and economic difficulties (odds ratio, 1.24; 95% confidence interval, 1.10-1.50). The mean score of reported generic health status assessed by the EQ-5D visual analogue scale was 65.9 (standard deviation = 20.1) in patients with itch, compared with 74.7 (standard deviation = 18.0) in patients without itch (P < 0.001) and 74.9 (standard deviation = 15.7) in controls with itch compared with 82.9 (standard deviation = 15.6) in controls without itch (P < 0.001). Itch contributes substantially to the psychological disease burden in dermatological patients, and the management of patients should include access to multidisciplinary care.

18 January 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
CSChristina Schut
Christina Schut
FDFlorence J. Dalgard
Florence J. Dalgard
ABAnthony Bewley
Anthony Bewley
AEAndrea W.M. Evers
Andrea W.M. Evers
UGUwe Gieler
Uwe Gieler
TCthe ESDAP Study collaborators
the ESDAP Study collaborators
Background Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective interventions. BDD symptoms are more prevalent in patients with dermatological conditions than the general population, but there are no large sample studies comparing the prevalence of BDD symptoms between patients with dermatological conditions and healthy skin controls. Objectives To compare the prevalence of BDD symptoms between patients with different dermatological conditions and healthy skin controls and to describe sociodemographic, physical and psychological factors associated with BDD symptoms to identify patients who may have a particularly high chance of having this condition. Methods This observational cross-sectional, comparative multi-centre study included 8295 participants: 5487 consecutive patients with different skin diseases (56% female) recruited among dermatological out-patients at 22 clinics in 17 European countries and 2808 healthy skin controls (66% female). All patients were examined by a dermatologist. BDD symptoms were assessed by the Dysmorphic Concern Questionnaire (DCQ). Sociodemographic data, information on psychological factors and physical conditions were collected. Each patient was given a dermatological diagnosis according to ICD-10 by a dermatologist. Results The participation rate of invited dermatological patients was 82.4% on average across all centres. BDD symptoms were five times more prevalent in patients with dermatological conditions than in healthy skin controls (10.5% vs. 2.1%). Patients with hyperhidrosis, alopecia and vitiligo had a more than eleven-fold increased chance (adjusted Odds Ratio (OR) > 11) of having BDD symptoms compared to healthy skin controls, and patients with atopic dermatitis, psoriasis, acne, hidradenitis suppurativa, prurigo and bullous diseases had a more than six-fold increased chance (adjusted OR > 6) of having BDD symptoms. Using a logistic regression model, BDD symptoms were significantly related to lower age, female sex, higher psychological stress and feelings of stigmatisation. Conclusions This study reveals that clinical BDD symptoms are significantly associated with common dermatological diseases. As such symptoms are associated with higher levels of psychological distress and multiple unhelpful consultations, general practitioners and dermatologists should consider BDD and refer patients when identified to an appropriate service for BDD screening and management.

PCPavel Chernyshov
Pavel Chernyshov
AFAndrew Finlay
Andrew Finlay
Lucia Tomas-AragonesLucia Tomas-Aragones
Lucia Tomas-Aragones
FPFrancoise Poot
Francoise Poot
FSFrancesca Sampogna
Francesca Sampogna
Christos C. ZouboulisChristos C. Zouboulis
Christos C. Zouboulis
Knowledge on hidradenitis suppurativa/acne inversa (HS) is rapidly increasing. HS has a profound impact on patients and their family life. Several factors, such as comorbidities, unemployment and HS severity, make this impact even more severe. The most widely used instrument to measure this impact is the dermatology-specific DLQI. We also identified six HS-specific health-related quality of life (HRQoL) instruments. Of them, HIDRAdisk, HSIA, HiSQOL and HSQoL-24 are better validated but there is still lack of experience of its use. Several treatment methods showed positive effect on patients’ HRQoL. Surgery remains a method with a substantial positive effect on HRQoL. Several studies confirming a positive effect of adalimumab on the HRQoL of patients with HS were published during the last three years. Data on the influence of several other biologics on HRQoL of HS patients are controversial or based on studies with a small number of patients.

29 August 2019 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
GTG. Titeca
G. Titeca
LGL. Goudetsidis
L. Goudetsidis
BFB. Francq
B. Francq
FSFrancesca Sampogna
Francesca Sampogna
UGU. Gieler
U. Gieler
FPF. Poot
F. Poot